Local dual delivery of a chemotherapy and an anti-angiogenic agent from an injectable functionalized biodegradable biomaterial system for the treatment of gliomas
从可注射的功能化生物可降解生物材料系统局部双重递送化疗药物和抗血管生成药物,用于治疗神经胶质瘤
基本信息
- 批准号:10565921
- 负责人:
- 金额:$ 10.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-16 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Alkylating AgentsAngiogenesis InhibitorsAngiogenic FactorAngiogenic ProteinsAntibodiesApoptosisBiocompatible MaterialsBiological AssayBrainBrain NeoplasmsBypassCD44 geneCancer Cell GrowthCarmustineCell SurvivalCellsChemotherapy and/or radiationDefectDevelopmentDiagnosisDiseaseDrug Delivery SystemsENG geneElementsEndothelial CellsEnvironmentGliomaGoalsHalf-LifeHigh Pressure Liquid ChromatographyHumanImmunotherapyImplantIn VitroInjectableKineticsLocal TherapyMalignant GliomaMalignant neoplasm of brainMeasuresMemory impairmentMethodsMinocyclineModelingMorphologyMusNitrosourea CompoundsOperative Surgical ProceduresOrganOutcomePatientsPharmaceutical PreparationsPrognosisProteinsQuality of lifeRadiation therapyRattusRodentScanning Electron MicroscopySiteSystemTherapeutic AgentsToxic effectTumor VolumeTumor WeightsWestern BlottingWorkantibody conjugateblood vessel developmentblood-brain barrier crossingchemotherapycostcytotoxicdesigndrug efficacyeffective therapyglioma cell lineimplantable deviceimprovedin vivoin vivo Modelinterestlight scatteringneoplastic cellnew technologynovel therapeuticsparticlepatient prognosisresponsescaffoldsubcutaneoustemozolomidetumortumor growthtumor progression
项目摘要
PROJECT SUMMARY/ABSTRACT
Each year, around 10,000 patients in the US are diagnosed with gliobastoma multiforme (GBM),
which is the most common, aggressive and high-grade form of these brain tumors (82% of
malignant gliomas). Currently, the median survival for this disease is around 21 months after
diagnosis. Despite advances in the different methods of therapy (i.e. radiotherapy,
immunotherapy and chemotherapy), the prognosis for gliomas has not been dramatically
improved through the years. For tumors located in the brain, systemic delivery of agents has to
overcome many obstacles for the successful delivery of the drug to the site including the critical
step of having to cross the blood brain barrier (BBB). Due to the difficulty and high cost related
to developing new therapeutics, focus should be placed on optimizing available drugs by ways
such as delivering them locally using biomaterials. Local delivery of an anti-angiogenic factor
(i.e. minocycline) and systemic delivery of a chemotherapy agent (i.e. bis-chloroethylnitrosourea
(BCNU) or temozolomide (TMZ)) has been shown to improve median survival compared to the
delivery of the systemic delivery of the chemotherapy agent alone in a rodent glioma model.
Thus far, a lot of studies have been performed to study the delivery of both of these factors
systemically or one factor systemically and the other factor locally to treat gliomas. However, the
local deliver of both of these agents by combining both of them in an implantable device has not
been investigated. It is hypothesized that the local delivery of both a chemotherapy agent that
will impede the growth of cancer cells and an anti-angiogenic factor that will block blood vessel
formation can better inhibit cancer progression compared to the delivery of these drugs
systemically or locally alone. An ideal therapy should target tumor cells and avoid damaging
non-tumor cells which can result in memory impairment, decline in brain function and low quality
of life. CD44 and CD105 have been shown to be highly expressed on human glioma cell lines
and endothelial cells, respectively and thus we further hypothesized that biomaterials
functionalized with antibody against these markers can decrease non-targeted toxicity and
increase bioactivity on targeted cells. The overall goal of this proposal is to develop a
biodegradable composite system that has the ability to sustain the release of a chemotherapy
and an anti-angiogenic agent and target cells of interest for glioma which may also be applied to
other tumor types. The results from this work will contribute to the development of more
effective therapies for the treatment of brain gliomas.
项目总结/摘要
每年,美国约有10,000名患者被诊断患有多形性胶质母细胞瘤(GBM),
这是最常见的,侵略性和高级别的形式,这些脑肿瘤(82%的
恶性神经胶质瘤)。目前,这种疾病的中位生存期约为21个月,
诊断.尽管在不同的治疗方法(即放射治疗,
免疫疗法和化学疗法),神经胶质瘤的预后并不显着
这些年来有所改善。对于位于脑中的肿瘤,药剂的全身递送必须
克服了许多障碍,成功地将药物输送到该部位,包括关键的
必须穿过血脑屏障(BBB)的步骤。由于相关的难度和高成本
为了开发新的治疗方法,重点应该放在优化现有的药物上,
例如使用生物材料局部递送它们。抗血管生成因子的局部递送
(i.e.米诺环素)和化疗剂(即双-氯乙基亚硝基脲)的全身递送
(BCNU)或替莫唑胺(TMZ))已被证明可以改善中位生存期相比,
在啮齿动物神经胶质瘤模型中单独全身递送化疗剂的递送。
到目前为止,已经进行了大量的研究来研究这两种因素的传递
系统地或一种因素系统地和另一种因素局部地治疗神经胶质瘤。但
通过在可植入装置中组合这两种药剂来局部递送这两种药剂,
被调查了假设局部递送化疗剂,
会阻碍癌细胞的生长,并且是一种抗血管生成因子,
与这些药物的递送相比,
系统地或局部地单独地。理想的治疗方法应该靶向肿瘤细胞,
非肿瘤细胞,可导致记忆障碍,脑功能下降和低质量
生命CD 44和CD 105在人脑胶质瘤细胞系中高度表达
和内皮细胞,因此我们进一步假设,
用针对这些标志物的抗体功能化可以降低非靶向毒性,
增加对靶细胞生物活性。本提案的总体目标是制定一个
具有持续释放化疗药物的能力的可生物降解的复合系统
以及抗血管生成剂和神经胶质瘤的目标靶细胞,
其他肿瘤类型这项工作的成果将有助于发展更多的
治疗脑胶质瘤的有效方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sue Anne Chew其他文献
Sue Anne Chew的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sue Anne Chew', 18)}}的其他基金
Bridges to the Baccalaureate Research Training Program at The University of Texas Rio Grande Valley
通往德克萨斯大学里奥格兰德河谷分校学士学位研究培训计划的桥梁
- 批准号:
10459312 - 财政年份:2020
- 资助金额:
$ 10.9万 - 项目类别:
Bridges to the Baccalaureate Research Training Program at The University of Texas Rio Grande Valley
通往德克萨斯大学里奥格兰德河谷分校学士学位研究培训计划的桥梁
- 批准号:
10675057 - 财政年份:2020
- 资助金额:
$ 10.9万 - 项目类别:
Local dual delivery of a chemotherapy and an anti-angiogenic agent from an injectable functionalized biodegradable biomaterial system for the treatment of gliomas
从可注射的功能化生物可降解生物材料系统局部双重递送化疗药物和抗血管生成药物,用于治疗神经胶质瘤
- 批准号:
10359107 - 财政年份:2020
- 资助金额:
$ 10.9万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 10.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 10.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 10.9万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 10.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 10.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 10.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 10.9万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 10.9万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 10.9万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7537218 - 财政年份:2008
- 资助金额:
$ 10.9万 - 项目类别:














{{item.name}}会员




